In the newest episode of the pharmaphorum podcast, editor in chief Jonah Comstock speaks with Mohammed Issa, vice president of commercial at US Janssen Neuroscience.
BenevolentAI has discovered a second novel target for idiopathic pulmonary fibrosis (IPF), which AstraZeneca has added to its drug development portfolio, resulting in a milestone payment to the Lon
As the world and the UK continues its march out of the pandemic’s shadow, the pharmaceutical and life sciences sector has been squarely in the spotlight.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
